Acuren Corp
NYSE:TIC

Watchlist Manager
Acuren Corp Logo
Acuren Corp
NYSE:TIC
Watchlist
Price: 7.45 USD -22.07% Market Closed
Market Cap: $829.2m

Acuren Corp
Investor Relations

Acuren Corp. engages in providing nondestructive testing, inspection, engineering and lab testing services. The company is headquartered in Tomball, Texas. The company went IPO on 2023-10-12. The firm provide these essential and often compliance-mandated (often at customer locations) services in the industrial space and are focused on the recuring maintenance needs of its customers. The firm operates in the service category referred to as Testing, Inspection and Certification (TIC). These activities include Nondestructive Testing (NDT) techniques such as radiography, ultrasonic testing, magnetic particle inspection, penetrant testing, and visual inspection. NDT activities include inspection and evaluation of industrial equipment through various technology-enabled methods to ensure asset integrity, avoid costly accidents and comply with regulatory requirements without destroying the asset or component. The company operates from approximately 119 service centers and over 22 engineering and lab facilities. The company operates in the United States and Canada, and has limited operations located in the United Kingdom.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q4 2025
Call Date
Mar 12, 2026
AI Summary
Q4 2025

Leadership: Ben Heraud named CEO effective March 31, 2026; Tal Pizzey will remain on the Board and advise through the transition.

Scale & performance: Combined 2025 revenue was $2.1 billion (up ~4% constant currency), adjusted EBITDA $312 million (14.8% margin); Q4 revenue $508 million with adjusted EBITDA of $76.4 million.

Guidance: 2026 revenue $2.15 billion–$2.25 billion; adjusted EBITDA $330 million–$355 million; Q1 revenue $470 million–$485 million and adjusted EBITDA $55 million–$60 million.

Integration & cost synergies: $25 million of targeted annual cost synergies, roughly half expected in 2026 and full run-rate by mid-2027; integration execution said to be ahead of schedule.

Commercial traction & cross-sell: Management highlighted early cross-selling wins (notably a multi-year bridge engagement combining LiDAR, engineering and inspection) and material data center traction with 2025 data center revenue ~ $70 million and line of sight to nearly $100 million.

Margin actions & compensation: Q4 gross margins expanded across all segments; 2026 EBITDA guidance includes an $8 million headwind tied to reclassifying NV5 short-term incentive from equity to cash to align market compensation.

Capital allocation: Board authorized a $200 million share repurchase program while keeping focus on deleveraging (long-term net leverage target < 3x) and opportunistic tuck-ins.

Key Financials
Revenue (2025 full year, combined)
$2.1 billion
Adjusted EBITDA (2025 full year, combined)
$312 million
Adjusted EBITDA margin (2025 full year, combined)
14.8%
Total revenue (Q4 2025)
$508 million
Adjusted gross profit (2025 full year, combined)
$794 million
Adjusted gross margin (2025 full year, combined)
37.6%
Adjusted gross profit (Q4 2025)
$197 million
Adjusted gross margin (Q4 2025)
38.8%
I&M revenue (2025 full year)
approximately $1.1 billion
I&M adjusted gross margin (2025 full year)
27.8%
I&M revenue (Q4 2025)
$258 million
I&M adjusted gross margin (Q4 2025)
28.2%
CE revenue (2025 full year, combined)
$714 million
CE adjusted gross margin (2025 full year)
47.0%
CE revenue (Q4 2025, combined)
$181 million
CE adjusted gross margin (Q4 2025)
46.9%
Geospatial revenue (2025 full year, combined)
$298 million
Geospatial adjusted gross margin (2025 full year)
51.5%
Geospatial revenue (Q4 2025, combined)
$70 million
Geospatial adjusted gross margin (Q4 2025)
57.2%
Backlog (CE and GEO year-end)
$1.07 billion
Data center revenue (2025)
nearly $70 million
Adjusted SG&A (Q4 2025)
$124 million
Adjusted EBITDA (Q4 2025)
$76.4 million
Operating cash flow (2025 reported)
$95 million
CapEx (2025 reported)
$34 million (2.2% of revenue)
Combined CapEx (2025)
$56 million (2.7% of revenue)
Liquidity (year-end)
$551 million
Cash and cash equivalents (year-end)
approximately $440 million
Available capacity under revolver (year-end)
$111 million
Term loan debt (year-end)
approximately $1.6 billion
Private placement (Oct)
$250 million (20.8 million shares and prefunded warrants)
Integration synergy target
$25 million annualized
Stock-compensation reclassification impact (2026)
$8 million
Net interest expense (2026 expectation)
$95 million to $105 million
Cash taxes (2026 expectation)
$20 million to $30 million
Free cash flow outlook (2026)
Expected healthy conversion from adjusted EBITDA (no specific dollar amount given)
Share repurchase authorization
$200 million
Other Earnings Calls

Management

Mr. Talman B. Pizzey
President, CEO & Director
No Bio Available
Ms. Fiona E. Sutherland
General Counsel & Corporate Secretary
No Bio Available
Ms. Kristin B. Schultes
Chief Financial Officer
No Bio Available
Anthony Gaucher
Chief Human Resources Officer
No Bio Available
Mr. Frank Noble
Executive Vice President of Operations - US
No Bio Available

Contacts

Address
TEXAS
Tomball
14434 Medical Complex Drive, #100
Contacts
+18002187450
www.acuren.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett